Literature DB >> 12900528

Analgesic efficacy of etoricoxib in primary dysmenorrhea: results of a randomized, controlled trial.

Kerstin Malmstrom1, Paul Kotey, Nicole Cichanowitz, Stephen Daniels, Paul J Desjardins.   

Abstract

OBJECTIVE: To determine the efficacy of etoricoxib in the treatment of primary dysmenorrhea.
METHODS: Seventy-three women were randomly assigned to receive single oral doses of etoricoxib 120 mg, placebo, or naproxen sodium 550 mg at the onset of moderate to severe pain associated with menses. During 3 consecutive menstrual cycles in this double-blind, 3-period, crossover study, pain intensity and pain relief were assessed over the 24-hour period following dosing, and global ratings of therapy were made at 8 and 24 h after dosing. Tolerability was assessed by spontaneous reports of adverse experiences.
RESULTS: Etoricoxib 120 mg provided analgesic efficacy superior to placebo for the primary endpoint, total pain relief over 8 h (TOPAR8, p<0.001), and for all secondary endpoints (p<0.050). The analgesic effect of etoricoxib 120 mg over the first 8 h was similar to that of naproxen sodium 550 mg. All treatments were well tolerated.
CONCLUSIONS: Etoricoxib 120 mg provided rapid and sustained analgesia that was superior to placebo and similar to that of naproxen sodium 550 mg. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12900528     DOI: 10.1159/000072735

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  9 in total

Review 1.  Dysmenorrhoea.

Authors:  Michelle L Proctor; Cynthia M Farquhar
Journal:  BMJ Clin Evid       Date:  2007-03-01

Review 2.  Dysmenorrhoea.

Authors:  Pallavi Manish Latthe; Rita Champaneria; Khalid Saeed Khan
Journal:  BMJ Clin Evid       Date:  2011-02-21

Review 3.  Clinical use and pharmacological properties of selective COX-2 inhibitors.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2007-11-13       Impact factor: 2.953

Review 4.  Nonsteroidal anti-inflammatory drugs for dysmenorrhoea.

Authors:  Jane Marjoribanks; Reuben Olugbenga Ayeleke; Cindy Farquhar; Michelle Proctor
Journal:  Cochrane Database Syst Rev       Date:  2015-07-30

5.  Efficacy and safety of over-the-counter analgesics for primary dysmenorrhea: A network meta-analysis.

Authors:  Wenbo Nie; Ping Xu; Chunyan Hao; Yingying Chen; Yanling Yin; Lisheng Wang
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.889

6.  Etoricoxib for arthritis and pain management.

Authors:  Peter Brooks; Paul Kubler
Journal:  Ther Clin Risk Manag       Date:  2006-03       Impact factor: 2.423

7.  Rofecoxib for dysmenorrhoea: meta-analysis using individual patient data.

Authors:  Jayne E Edwards; R Andrew Moore; Henry J McQuay
Journal:  BMC Womens Health       Date:  2004-07-20       Impact factor: 2.809

8.  Comparison of the efficacy and safety of non-steroidal anti-inflammatory drugs for patients with primary dysmenorrhea: A network meta-analysis.

Authors:  Xuan Feng; Xiaoyun Wang
Journal:  Mol Pain       Date:  2018-03-27       Impact factor: 3.395

Review 9.  The Effect of Micronutrients on Pain Management of Primary Dysmenorrhea: a Systematic Review and Meta-Analysis.

Authors:  Marzieh Saei Ghare Naz; Zahra Kiani; Farzaneh Rashidi Fakari; Vida Ghasemi; Masoumeh Abed; Giti Ozgoli
Journal:  J Caring Sci       Date:  2020-03-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.